News
Public · Published
Accendra Health Announces Extension of $150 Million Receivables Sale Program To 2029
Accendra Health said it amended its Receivables Purchase Agreement on October 29, 2026, extending the program's scheduled termination to October 2029. The receivables sale program remains $150 million in size, unchanged by the amendment.
Published:
Updated:
What happened
Accendra Health said it amended its Receivables Purchase Agreement on October 29, 2026, extending the program’s scheduled termination to October 2029. The receivables sale program remains $150 million in size, unchanged by the amendment.
Confirmed
Global impact / market context
The extension gives Accendra Health continued access to a way of turning customer invoices into cash before they are paid, supporting cash available for operations. Because the program size is unchanged, the announcement extends its duration rather than adding stated funding capacity.
Analyst inference
The extension keeps the receivables sale arrangement available through October 2029, while its size stays at $150 million. This may help Accendra Health convert unpaid customer bills into cash under the program, supporting cash available for operations without increasing the disclosed funding amount.
Analyst inference
What to watch
- Watch for company disclosures about use of the program and any changes in its size or terms, since the announcement confirms the extension but not expanded funding. Analyst inference
- The amendment extends the scheduled termination date to October 2029; the release does not specify other amended terms or provide further details about the banking partner. Confirmed
- Future financial updates could show whether the extended receivables sale program helps maintain cash available for operations, especially if customer invoices take longer to collect. Analyst inference
Evidence
- Original source link unavailable